NCT07607678: A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab

Sponsor: Boehringer Ingelheim. Phase: PHASE1. Conditions: Advanced Solid Cancer, Metastatic Solid Cancer